Research & Development
Investigational Therapeutic for Episodic Cardiovascular Conditions
We are studying our lead investigational candidate, etripamil, for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), wherever their episodes may occur.
Clinical trials are a critical part of the drug development process designed to assess an investigational agent’s safety and effectiveness in treating a disease, adding to the scientific body of knowledge on diseases and how they may be treated.
For information regarding access to Milestone’s clinical trials, please visit clinicaltrials.gov.
Phase 3 Clinical Program
Milestone’s pivotal Phase 3 program of etripamil in PSVT, which was designed in consultation with U.S. and European Union regulatory authorities, consists of three distinct trials evaluating the safety and efficacy of etripamil in at-home settings and without the need for medical supervision.
Completed
Ongoing global safety trial and the largest trial ever conducted in PSVT
See a description of our Node-303 Phase 3 clinical trial clinical.trials.gov
Phase 2 Clinical Program
Actively recruiting
Open-label, phase 2, pharmacokinetic, safety and efficacy trial in pediatric population
See a description of our NODE-202 Phase 2 clinical trial clinical.trials.gov
.png){kind=small}